Skip to main content
Figure 1 | Journal of Neuroinflammation

Figure 1

From: CD80+ and CD86+B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis

Figure 1

Gating strategy for CD80 and CD86 quantification in PBMCs. PBMCs from a representative HAM/TSP patient were stained with CD3-, CD19-, CD80- and CD86-specific monoclonal antibodies and analyzed by flow cytometry. P1 (in blue contours) represents the lymphocyte gate. Percentages of CD80+ and CD86+ cells within the lymphocyte gate (P1) are indicated in the respective quadrants (red contours).

Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094